This bill mandates that various health insurance providers in New Jersey, including hospital service corporations, medical service corporations, health service corporations, individual and group health insurance policies, health maintenance organizations, and health benefits plans, must cover expenses related to the purchase and use of continuous glucose monitoring systems for the treatment of glycogen storage disease. The coverage must be provided to the same extent as for any other medical condition under the respective contracts or policies. This requirement applies to contracts and policies that are delivered, issued, executed, or renewed on or after the effective date of the act.

The bill also stipulates that the State Health Benefits Commission and the School Employees Health Benefits Commission must ensure that all contracts purchased by them after the effective date provide the same coverage for continuous glucose monitoring systems. The act is set to take effect on the first day of the seventh month following its enactment, ensuring that all relevant health benefits plans comply with this new requirement.